Related Experiment Video
Updated: Feb 23, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Early Versus Delayed Initiation of Pharmacological Venous Thromboembolism Prophylaxis After an Intracranial
Andrew C Faust1, Christopher K Finch, April C Hurdle
1*Department of Pharmacy, Methodist University Hospital †Department of Clinical Pharmacy, The University of Tennessee College of Pharmacy §Department of Neurology and Neurosurgery, Semmes-Murphey Neurologic Institute, University of Tennessee Health Sciences Center, Memphis, TN ‡Department of Pharmacy, Critical Care Pharmacy Specialist, Texas Health Resources Presbyterian Hospital of Dallas, Dallas, TX.
Background:
Intracranial hemorrhage (ICH) accounts for up to 20% of all strokes with and carries an approximate 50% 30-day mortality. The risk of venous thromboembolism (VTE) is markedly higher in patients with ICH compared with ischemic strokes, but the optimal time to initiate pharmacological prophylaxis is ill-defined.
Design:
Retrospective analysis.
Setting:
University-affiliated, tertiary care center.
Patients:
Patients admitted for a nontraumatic ICH who received pharmacological VTE prophylaxis during their first 30 hospital days.
Results:
Of the 793 patients evaluated, 400 were included [142 (35.5%) early]. Rebleeding event rates were similar for early versus late [8 (5.6%) vs. 13 (5.0%), P=0.80] and rates of hospital-acquired VTEs were not statistically different [1 (0.7%) vs. 8 (3.1%), P=0.17]. The median time from admission to the first dose of pharmacological prophylaxis was similar in patients who experienced rebleeding versus those that did not [74 h (range, 38 to 110.5 h) vs. 63 h (range, 45 to 90.5 h), P=0.69]. There was a longer median time from admission to the first dose of pharmacological prophylaxis in patients who developed a VTE during the initial hospitalization versus those who did not [108 h (range, 73.3 to 187 h) vs. 63 h (range, 44.5 to 90 h), P=0.005].
Conclusions:
Initiation of early pharmacological prophylaxis in ICH patients did not appear to increase the risk of rebleeding nor decrease the risk of VTE. Among those patients who did develop VTE during hospitalization, there was a longer median time from admission to the first dose of pharmacological prophylaxis.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

